Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ESPR
Previous Symbol
CUSIPN/A
Phone734-887-3903
Debt
Debt-to-Equity RatioN/A
Current Ratio3.98
Quick Ratio3.98
Price-To-Earnings
Trailing P/E Ratio-6.64
Forward P/E Ratio-7.15
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.91 per share
Price / Book9.43
Profitability
EPS (Most Recent Fiscal Year)($6.98)
Net Income$-166,980,000.00
Net MarginsN/A
Return on Equity-93.76%
Return on Assets-79.24%
Miscellaneous
Employees57
Outstanding Shares26,810,000
Market Cap$1.35 billion
OptionableOptionable
Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions
What is Esperion Therapeutics' stock symbol?
Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."
How were Esperion Therapeutics' earnings last quarter?
Esperion Therapeutics Inc (NASDAQ:ESPR) announced its earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.64) by $0.22. During the same period in the previous year, the business earned ($1.86) EPS. View Esperion Therapeutics' Earnings History.
When is Esperion Therapeutics' next earnings date?
What price target have analysts set for ESPR?
13 Wall Street analysts have issued 12-month price targets for Esperion Therapeutics' shares. Their forecasts range from $32.50 to $153.00. On average, they expect Esperion Therapeutics' share price to reach $77.8846 in the next year. This suggests a possible upside of 68.1% from the stock's current price. View Analyst Price Targets for Esperion Therapeutics.
What is the consensus analysts' recommendation for Esperion Therapeutics?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 2 sell ratings, 1 hold rating, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Esperion Therapeutics.
What are Wall Street analysts saying about Esperion Therapeutics stock?
Here are some recent quotes from research analysts about Esperion Therapeutics stock:
- 1. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (11/6/2018)
- 2. Chardan Capital analysts commented, "We revise our p-value estimate on the imbalance of deaths seen in the pooled phase II/III data for bempedoic acid (BA) from p<0.05 to p=0.06-0.11 after consulting separately with 3 professional biostatisticians. We remain cautious on ESPR and upcoming Study 2 phase III data in September (see page 2). Esperion reported positive efficacy data from the 52-week phase III study (Study 1; NCT02666664) of BA in 2,230 inadequately-treated ASCVD patients. However, the company reported an imbalance of deaths in Study 1, namely 13 deaths (0.87%, 13/1,488) in the BA-treated group, vs. 2 deaths (0.27%, 2/742) in the placebo-treated group. Since Esperion provided no p-value on this imbalance of deaths, and because there was to us insufficient information on the exact nature of deaths (e.g."" (7/20/2018)
Has Esperion Therapeutics been receiving favorable news coverage?
Media coverage about ESPR stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Esperion Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Esperion Therapeutics' key competitors?
Some companies that are related to Esperion Therapeutics include GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), Agios Pharmaceuticals (AGIO), Horizon Pharma (HZNP), FibroGen (FGEN), Emergent Biosolutions (EBS), Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT) and Endo International (ENDP).
Who are Esperion Therapeutics' key executives?
Esperion Therapeutics' management team includes the folowing people:
- Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 57)
- Dr. Narendra D. Lalwani, Exec. VP of R&D and COO (Age 65)
- Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 36)
- Ms. Marianne Andreach, Sr. VP of Product Planning
- Ms. Ashley Hall, Sr. VP of Global Regulatory Affairs & Policy
Who are Esperion Therapeutics' major shareholders?
Esperion Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BB Biotech AG (12.25%), Partner Fund Management L.P. (7.35%), BlackRock Inc. (7.01%), Credit Suisse AG (3.62%), Wasatch Advisors Inc. (2.08%) and FMR LLC (1.92%). Company insiders that own Esperion Therapeutics stock include Boxer Capital, Llc, Dov A Md Goldstein, Gilbert S Omenn, Nicole Vitullo, Roger S Newton and Target N V Biotech. View Institutional Ownership Trends for Esperion Therapeutics.
Which institutional investors are selling Esperion Therapeutics stock?
ESPR stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Wells Fargo & Company MN, FMR LLC, Credit Suisse AG, Pinnacle Associates Ltd., Connor Clark & Lunn Investment Management Ltd., Seven Eight Capital LP and Virtus ETF Advisers LLC. Company insiders that have sold Esperion Therapeutics company stock in the last year include Boxer Capital, Llc, Nicole Vitullo and Roger S Newton. View Insider Buying and Selling for Esperion Therapeutics.
Which institutional investors are buying Esperion Therapeutics stock?
ESPR stock was bought by a variety of institutional investors in the last quarter, including BB Biotech AG, Bamco Inc. NY, Bellevue Group AG, BlackRock Inc., Pictet Asset Management Ltd., American Century Companies Inc., Trexquant Investment LP and Wasatch Advisors Inc.. Company insiders that have bought Esperion Therapeutics stock in the last two years include Gilbert S Omenn and Target N V Biotech. View Insider Buying and Selling for Esperion Therapeutics.
How do I buy shares of Esperion Therapeutics?
Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Esperion Therapeutics' stock price today?
One share of ESPR stock can currently be purchased for approximately $46.32.
How big of a company is Esperion Therapeutics?
Esperion Therapeutics has a market capitalization of $1.35 billion. The biopharmaceutical company earns $-166,980,000.00 in net income (profit) each year or ($6.98) on an earnings per share basis. Esperion Therapeutics employs 57 workers across the globe.
What is Esperion Therapeutics' official website?
How can I contact Esperion Therapeutics?
Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]
MarketBeat Community Rating for Esperion Therapeutics (NASDAQ ESPR)
MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe ESPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
